ArticleInternational braz j urol : official journal of the Brazilian Society of Urology
Extraperitoneal Single-Port Robot-Assisted Bilateral Retroperitoneal Lymph Node Dis-section for Primary Non-Seminomatous Germ Cell Tumor: Technique and Surgical Considerations.
Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRetroperitoneal lymph node dissection (RPLND) is an established treatment option for clinical stage I-II non-seminomatous germ cell tumors (NSGCT), among which bilateral template dissection represents the most oncologically rigorous approach (1, 2). Robot-assisted RPLND has demonstrated reduced surgical morbidity while maintaining oncologic equivalence to open surgery (3). However, the prevailing multiport transperitoneal approach requires extensive bowel mobilization for bilateral exposure, adding operative complexity and bowel-related complication risk (4-6). A completely extraperitoneal single-port approach may circumvent these limitations by avoiding peritoneal entry and visceral manipulation (7). MATERIALS AND
methodsWe present a 21-year-old male with clinical stage IIA NSGCT who underwent right radical orchiectomy and was found to have multiple enlarged retroperitoneal lymph nodes on CT. The procedure was performed using the da Vinci Xi system with the patient in the supine position. A 4.0-cm right pararectal incision was made to access the retroperitoneal space, and a single-port multichannel device was deployed. Robotic instruments were introduced in a chopstick configuration, including a 30° endoscope, monopolar scissors, and bipolar forceps. The bilateral ureters and great vessels were first exposed to delineate the standard boundaries of the bilateral template while establishing an adequate retroperitoneal working space. A split-and-roll technique was then applied from the right ureter medially, progressively skeletonizing and preserving the vascular structures through sharp dissection to achieve complete lymphadenectomy within the bilateral template, with meticulous clipping of lymphatic channels.
resultsOperative time was 175 minutes with an estimated blood loss of 35 mL. The patient resumed oral intake on postoperative day 1 and was discharged on day 2 (VAS: 2) without complications. Thirty-two lymph nodes were retrieved; three harbored teratoma (pN1). At 36-month follow-up, the patient remains disease-free with normal tumor markers and no retroperitoneal recurrence.
conclusionsTo our knowledge, this represents the first reported extraperitoneal single-port bilateral robot-assisted RPLND. This approach achieves oncologically thorough dissection while minimizing morbidity and facilitating rapid recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.